Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits

Lili Liu, Atlas Khan, Elena Sánchez, Francesca Zanoni, Yifu Li, Nicholas J. Steers, Olivia Balderes, Jun Y. Zhang, Priya Krithivasan, Robert A. LeDesma, Clara Fischman, Scott J. Hebbring, John B. Harley, Halima Moncrieffe, Leah C. Kottyan, Bahram Namjou, Theresa L. Walunas, Rachel Knevel, Soumya Raychaudhuri, Elizabeth W. Karlson, Joshua C. Denny, Ian B. Stanaway, David R. Crosslin, Thomas Rauen, Jürgen Floege, Frank Eitner, Zina Moldoveanu, Colin Reily, Barbora Knoppová, Stacy Hall, Justin T. Sheff, Bruce A. Julian, Robert Wyatt, Hitoshi Suzuki, Jingyuan Xie, Nan Chen, Shu‐Feng Zhou, Hong Zhang, Lennart Hammarström, Alexander Viktorin, Patrik K. E. Magnusson, Ning Shang, George Hripcsak, Chunhua Weng, Tatjana Rundek, Mitchell S.v. Elkind, Elizabeth C. Oelsner, R. Graham Barr, Iuliana Ionita‐Laza, Jan Novák, Ali G. Gharavi, Krzysztof Kiryluk

Abstract

Immunoglobulin A (IgA) is a critical mediator of mucosal immunity, yet its genetic regulation and causal links to disease have been poorly understood, particularly in non-European populations. This study performed a multi-ancestry genome-wide association study (GWAS) of serum IgA levels in 41,263 individuals, identifying 20 significant loci (11 novel). Functional analyses prioritized candidate genes and highlighted the role of T-cell regulation. Genetic correlations and Mendelian randomization revealed that while high IgA protects against certain infections and inflammatory conditions, it is a causal driver of IgA nephropathy. Notably, African ancestry is associated with higher IgA levels and a greater burden of IgA-increasing alleles.

Introduction

As the most abundant antibody class in the human body, IgA protects mucosal surfaces like the gut and respiratory tract. Despite its importance, the genetic architecture of serum IgA levels remained largely undefined, with previous research skewed toward European cohorts. This study aimed to map these genetic regulators across diverse populations and clarify whether observed associations between IgA levels and conditions like kidney disease or diabetes are causal or merely correlative.

Methods

The researchers conducted a multi-ancestry GWAS meta-analysis across 16 cohorts. To bridge the gap between genetic variants and biological function, they utilized:

  • Co-localization Analysis: Overlapping GWAS signals with expression Quantitative Trait Loci (eQTL) to identify target genes and cell types.
  • Mendelian Randomization (MR): Using genetic variants as instrumental variables to test for causal relationships between IgA levels and disease.
  • Phenome-wide Association Study (PheWAS): Testing a Polygenic Score (GPS) for IgA against thousands of clinical traits in the UK Biobank and eMERGE-III.

Key Insights and Ideas

The Ancestry Signature

A major finding was the consistent association of African ancestry with higher serum IgA levels. This trend was observed both when comparing broad ancestry groups and when examining the proportion of African ancestry within individuals. This suggests an evolutionary adaptation, where higher IgA might have provided a fitness advantage against specific mucosal pathogens.

Serum IgA levels across ancestries and by African ancestry proportion.

T-Cells as Regulators

While B-cells produce IgA, the study found that many genetic "switches" regulating IgA levels (such as TRAF3 and IL1R1) are primarily active in T-cells. This underscores that IgA production is not just a B-cell intrinsic process but is heavily regulated by T-cell signaling.

A Double-Edged Sword

The study revealed a complex trade-off in the clinical impact of IgA. Genetically higher IgA levels are protective against inflammatory bowel disease (IBD), celiac disease, and various infections. However, these same genetic factors increase the risk for IgA nephropathy, Type 2 diabetes, and higher BMI.

Using Mendelian Randomization, the authors established that elevated serum IgA is a causal factor for IgA nephropathy (OR 9.70 per standard deviation increase). This finding identifies IgA as a primary therapeutic target rather than just a disease biomarker.

Key Results

  • 20 Significant Loci: The study identified 20 independent genetic regions, 11 of which were novel.
  • Genetic Score Distribution: The Polygenic Score (GPS) for IgA was significantly higher in individuals of African ancestry, reflecting a higher frequency of IgA-increasing alleles.
  • Clinical Impact: The GPS was associated with 31 clinical traits, confirming IgA's broad influence on human health.
Distribution of normalized Polygenic Scores (GPS) for IgA across ancestry groups and allele frequency differences.

Limitations and Future Work

While this study is the largest multi-ancestry analysis of IgA to date, sample sizes for East Asian and Latinx populations remain smaller than for Europeans. Future work will investigate whether therapeutic lowering of serum IgA can treat IgA nephropathy without compromising its essential protective roles in mucosal immunity.

Summary updated

Abstract

Immunoglobulin A (IgA) mediates mucosal responses to food antigens and the intestinal microbiome and is involved in susceptibility to mucosal pathogens, celiac disease, inflammatory bowel disease, and IgA nephropathy. We performed a genome-wide association study of serum IgA levels in 41,263 individuals of diverse ancestries and identified 20 genome-wide significant loci, including 9 known and 11 novel loci. Co-localization analyses with expression QTLs prioritized candidate genes for 14 of 20 significant loci. Most loci encoded genes that produced immune defects and IgA abnormalities when genetically manipulated in mice. We also observed positive genetic correlations of serum IgA levels with IgA nephropathy, type 2 diabetes, and body mass index, and negative correlations with celiac disease, inflammatory bowel disease, and several infections. Mendelian randomization supported elevated serum IgA as a causal factor in IgA nephropathy. African ancestry was consistently associated with higher serum IgA levels and greater frequency of IgA-increasing alleles compared to other ancestries. Our findings provide novel insights into the genetic regulation of IgA levels and its potential role in human disease.
BibTeX
@inproceedings{liu2022genetic,
  author = {Lili Liu and Atlas Khan and Elena Sánchez and Francesca Zanoni and Yifu Li and Nicholas J. Steers and Olivia Balderes and Jun Y. Zhang and Priya Krithivasan and Robert A. LeDesma and Clara Fischman and Scott J. Hebbring and John B. Harley and Halima Moncrieffe and Leah C. Kottyan and Bahram Namjou and Theresa L. Walunas and Rachel Knevel and Soumya Raychaudhuri and Elizabeth W. Karlson and Joshua C. Denny and Ian B. Stanaway and David R. Crosslin and Thomas Rauen and Jürgen Floege and Frank Eitner and Zina Moldoveanu and Colin Reily and Barbora Knoppová and Stacy Hall and Justin T. Sheff and Bruce A. Julian and Robert Wyatt and Hitoshi Suzuki and Jingyuan Xie and Nan Chen and Shu‐Feng Zhou and Hong Zhang and Lennart Hammarström and Alexander Viktorin and Patrik K. E. Magnusson and Ning Shang and George Hripcsak and Chunhua Weng and Tatjana Rundek and Mitchell S.V. Elkind and Elizabeth C. Oelsner and R. Graham Barr and Iuliana Ionita‐Laza and Jan Novák and Ali G. Gharavi and Krzysztof Kiryluk},
  title = {{Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-34456-6},
}
Figure